Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprenone versus rabeprazole for gastrointestinal mucosal protection after PCI with dual antiplatelet therapy
ChiCTR2400079666Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of teprenone and rabeprazole in gastrointestinal mucosal injury (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Rate of total clinical benefit. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
teprenonerabeprazole
03
Conditions
gastrointestinal mucosal injury
Beyond the preview
Go deeper on ChiCTR2400079666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079666.